Circulating VEGF levels in breast cancer patients with bone metastases one month [clinicaltrials_resource:66becc421f25557696580fb3b85dbb29]
Zometa 4mg IV q4w, in combination with other antitumor agents one month after the initial dosing.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Circulating VEGF levels in breast cancer patients with bone metastases one month [clinicaltrials_resource:66becc421f25557696580fb3b85dbb29]
Zometa 4mg IV q4w, in combination with other antitumor agents one month after the initial dosing.
Bio2RDF identifier
66becc421f25557696580fb3b85dbb29
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:66becc421f25557696580fb3b85dbb29
measure [clinicaltrials_vocabulary:measure]
Circulating VEGF levels in breast cancer patients with bone metastases
time frame [clinicaltrials_vocabulary:time-frame]
description
Zometa 4mg IV q4w, in combinat ...... onth after the initial dosing.
identifier
clinicaltrials_resource:66becc421f25557696580fb3b85dbb29
title
Circulating VEGF levels in breast cancer patients with bone metastases one month
@en
type
label
Circulating VEGF levels in bre ...... ecc421f25557696580fb3b85dbb29]
@en